China’s Xi speaks with Trump by phone, discusses Taiwan and bilateral ties
Kenvue Inc stock has reached a new 52-week low, hitting a price of 16.06 USD. This milestone reflects a challenging year for the company, as its stock has seen a significant decline of 28.68% over the past year. According to InvestingPro data, the stock's RSI indicates oversold territory, while maintaining impressive gross profit margins of 58% and offering a substantial 5.11% dividend yield. The drop to this 52-week low underscores ongoing concerns among investors about the company's performance and market conditions. As Kenvue Inc navigates these difficulties, the market will be closely watching for any signs of recovery or further decline. InvestingPro analysis suggests the stock is currently undervalued, with analysts expecting net income growth this year. Discover 10+ additional exclusive insights about KVUE with an InvestingPro subscription, including detailed Fair Value analysis and comprehensive Pro Research Reports.
In other recent news, Kenvue Inc. has been the focus of several developments concerning its Tylenol product line. The European Medicines Agency (EMA) announced that there is no evidence linking paracetamol use during pregnancy to autism, countering claims made by U.S. President Donald Trump. Despite these concerns, Barclays has maintained its Equalweight rating on Kenvue, with a price target of $20.00. Meanwhile, Evercore ISI has lowered its price target for Kenvue to $18.00, following an FDA announcement to initiate changes to the safety label of acetaminophen, the active ingredient in Tylenol.
Goldman Sachs has also reiterated its Neutral rating on Kenvue, maintaining a $22.00 price target, amid potential reports from HHS Secretary RFK Jr. examining links between Tylenol use during pregnancy and autism. The FDA has also sent notices to physicians and begun the process to change the product's safety label. These developments come as the Trump administration held a briefing suggesting potential links between Tylenol and autism, a stance that differs from mainstream medical opinions. Investors are closely monitoring these updates as they unfold.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.